Fig. 4: Assessment of MEASs’ immune efficacy in vitro. | npj Vaccines

Fig. 4: Assessment of MEASs’ immune efficacy in vitro.

From: A multi-epitope subunit vaccine providing broad cross-protection against diverse serotypes of Streptococcus suis

Fig. 4

a The mouse immunization procedure and blood collection timeline, with PBS+adjuvant serving as the control. The red box below highlights the determination of antibody titers in serum after three immunizations with MEASs. b The expression of IgG1, IgG2a and IgG2b in serum of each group after three times of immunization through ELISA. c Isolated spleen lymphocytes after three immunizations, and lymphocyte proliferation was measured using CCK 8 after incubation with MEAS 1, MEAS 2 and MEAS 3 for 48 h. d The expression of IFN-γ and IL-4 in the supernatant of lymphocytes incubated with MEAS 1, MEAS 2 and MEAS 3 by ELISA. e The proportion of CD3+CD4+ and CD3+CD8+ T lymphocytes was determined by flow cytometry. f The ratio of CD3+CD4+ / CD3+CD8+ in different groups. Significance (P)-value summary analysed by Unpaired two-tailed Student’s t-test (*P < 0.05; **P < 0.01; ***P < 0.001; ns no significance). Figure 4a mouse model was created in BioRender. KAKA, L. (2024) BioRender.com/e31e489.

Back to article page